

HCV in 2014: F0 – F2

Treat Now or Wait

Yves Benhamou
Hôpital Pitié Salpêtrière
Paris

Available Anti-HCV Drugs Q1 2014

Pegylated IFN/Ribavirin	2001
Telaprevir	2011
Boceprevir	2011
Simeprevir	2013
Sofosbuvir	2013

Available Anti-HCV Drugs Q1 2014

Pegylated IFN/Ribavirin	2001	
Telaprevir	2011	Increased toxicity, DDI, Q8h
Boceprevir	2011	
Simeprevir	2013	
Sofosbuvir	2013	

Available Anti-HCV Drugs Q1 2014

Pegylated IFN/Ribavirin	2001	
Telaprevir	2011	Increased toxicity, DDI, Q8h
Boceprevir	2011	
Simeprevir	2013	
Sofosbuvir	2013	

PHC 2013



PHC 2014



New DAAs Active Against All HCV GT

	G1	G2	G3	G4
SOF/PR	Active	Inactive	Inactive	Active
SOF/R	Inactive	Active	Active	Inactive
SMV/PR	Active	Inactive	Inactive	Active

High SVR Rates in HCV Naive Patients

	G1	G2	G3	G4
SOF/PR	~ 90%			~ 95%
SOF/R		~ 90%	~ 90%	(~ 95%)
SMV/PR	~ 80%			~ 85%

High SVR Rates in HCV Treatment Failure Patients

	G1	G2	G3	G4
SOF/PR	?			(~ 90%)
SOF/R		~ 90%	~ 60%	(~ 90%)
SMV/PR	~ 50% - 85%			(~ 85%)?

New DAAs Well Tolerated

	SAEs	Discont for AEs
SOF/PR	~ 9%	~ 3%
SOF/R	~ 7%	~ 1%
SMV/PR	~ 3%	~ 3%

What Are We Waiting For ?

- **Current therapy**

- Highly active
- Well tolerated
- Almost all GT
- Shorten duration

- **Future therapy**

- SVR > 80% or 90% ??
- < 2% or 3 % Discont. For AEs ??
- GT 5 – 6 ??
- Less than 12/24W or therapy ??

What Are We Waiting For ?

- Current therapy
 - Highly active
 - Well tolerated
 - Almost all GT
 - Shorten duration

- Future therapy
 - SVR > 80% or 90% ??
 - < 2% or 3 % Discont. For AEs ??
 - GT 5 – 6 ??
 - Less than 12/24W or therapy ??

IFN FREE REGIMENS FOR ALL PATIENTS

MORE EXPENSIVE THERAPY

What Are We Waiting For ?

Drugs cost per month of treatment

Pegylated IFN	680 €
Ribavirin	140 €
Simeprevir	16.100 €
Sofosbuvir	18.650 €

What Are We Waitting For ?

	G1	G2	G3	G4
SOF/PR	58.400 € (116.800? €)			58.400 € (116.800 €?)
SOF/R		56.370 €	112.740 €	
SMV/PR	53.220 € (58.140 €)			53.220 € (58.140 €)

Future Regimens Even More Expensive

	G1 (Naive/NR)	Discont. For AEs	G4
SOF/SMV ± RBV (12W)	~ 95%	0%	(~ 95% ??)

Future Regimens Even More Expensive

Current Cost


	G1	G2	G3	G4
SOF/PR	58.400 € (116.800 €?)			58.400 € (116.800 €?)
SOF/R		56.370 €	112.740 €	
SMV/PR	53.220 € (58.140 €)			53.220 € (58.140 €)

Future Cost

SMV/SOF	104 250 €			104.250 €
---------	-----------	--	--	-----------

Conclusion

- **Treat Now**

- High SVR rate
- Good tolerability
- Almost all GT
- SVR is impacted by liver fibrosis grade (F0-2>F4)
 - F3-4 Patients should be treated now to prevent complications
 - F0-2 Patients can be treated now to prevent potent progression to F4 that may impact efficacy of future therapy.
- May help to reduce costs
 - « Rich » may be treated without IFN 
 - GT 1-4 : SMV+ SOF (off label)
 - GT 2-3 : SOF + RBV